Credit unions record strong growth but report advises sector to be ‘proactive’ in managing income and expenditure

The guidance is based on the existing trade environment, AbbVie said, and “does not reflect any trade policy shifts, including pharmaceutical sector tariffs, that could impact AbbVie’s business.”

Some analysts see the company as “a relatively safe haven” compared to its peers. AbbVie has a geographically diverse supply chain that will help mitigate tariff impacts, analysts from Raymond James said in a note before earnings.

The company also owns Irish-headquartered Allergan, which manufactures the world’s supply of Botox at its facility in Westport, Co Mayo. AbbVie’s aesthetics business, which includes Botox, missed Wall Street’s estimates in the period.

The segment is particularly sensitive to pullbacks in consumer spending because patients typically pay out of pocket. Botox will also be susceptible to potential tariffs on European countries since it’s made in Ireland.

The company is also seeking approval from the US Food and Drug Administration for a new, faster-acting wrinkle treatment that only lasts a few weeks. It’s meant to be an option for patients who want the effects of Botox, but cite fears of “looking unnatural,” AbbVie said.

AbbVie is also looking to Skyrizi and Rinvoq — a pair of newer autoimmune medicines — to make up for fading revenue from its ageing blockbuster Humira. Both beat estimates in the first quarter, with combined sales of $5.14bn (€4.5bn).

Strong sales from the two drugs helped the company surpass revenue expectations for the quarter. AbbVie recorded $13.34bn (€11.7bn) in overall sales, beating analyst estimates. Adjusted earnings for the quarter were $2.46 a share, above Wall Street’s expectations.

Shares in AbbVie rose 1.3% in premarket trading in New York. The North Chicago-based company had risen 1.5% this year through Thursday, outperforming a roughly 7% drop in the S&P 500 Index.

Investors have been focused on how companies are navigating existing tariffs and the potential for new levies to be imposed on pharmaceutical imports to the US.

Merck & Co. said Thursday that it expects to lose $200 million to already-announced tariffs, and Johnson & Johnson has said it will record a $400 million tariff expense this year.